The peptide Y includes the epitope recognized by omalizumab, the humanized anti-IgE monoclonal Ab approved for treatment of uncontrolled moderate to severe allergic asthma and antihistamine-resistant chronic idiopathic urticaria [11]. Here, IGHE is linked to allergic asthma.